Commit To Purchase InVivo Therapeutics Holdings Corp At $7.50, Earn 34.8% Annualized Using Options
StockOptionsChannel.com - Fri Oct 09, 10:48AM CDT
Investors eyeing a purchase of InVivo Therapeutics Holdings Corp shares, but tentative about paying the going market price of $8.63/share, might benefit from considering selling puts among the alternative strategies at their disposal. One...
NVIV: 8.81 (+0.47)
5 Stocks Under $10 Set to Soar
at The Street - Thu Oct 08, 11:13AM CDT
These stocks trading for less than $10 a share are within range of triggering breakout trades.
ONE: 2.30 (+0.07), VTL: 4.57 (-0.05), ALIM: 2.61 (+0.04), LOOK: 0.63 (-0.01), NVIV: 8.81 (+0.47), ESI: 3.80 (+0.01), NPTN: 7.17 (-0.04), DXM: 0.19 (unch)
InVivo Therapeutics to Present at the 2015 Aegis Growth Conference
Business Wire - Mon Oct 05, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, is scheduled to present at the 2015 Aegis Growth Conference to be held October 7-9, 2015 in Las Vegas, Nevada. The company's presentation will be on Friday, October 9 at 10:45 AM PDT.
NVIV: 8.81 (+0.47)
InVivo Therapeutics Featured in Bloomberg Businessweek Article
Business Wire - Fri Oct 02, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company was featured in a Bloomberg Businessweek article on Thursday, October 1.
NVIV: 8.81 (+0.47)
InVivo Therapeutics to Present at the Stem Cell Meeting on the Mesa
Business Wire - Tue Sep 29, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) announced today that Thomas Ulich, M.D., Chief Scientific Officer, will present at the annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 at the Estancia La Jolla Hotel in La Jolla, CA. The company's presentation will be on Wednesday, October 7 at 11:00 AM (PDT). A live webcast will be available at http://stemcellmeetingonthemesa.com/webcast/.
NVIV: 8.81 (+0.47)
InVivo Therapeutics' CEO and Chairman, Mark Perrin, Featured in MedGadget Article
Business Wire - Mon Sep 28, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman of the Board, was featured in a MedGadget article on Friday, September 25.
NVIV: 8.81 (+0.47)
InVivo Therapeutics to Present and Exhibit at the 65th CNS Annual Meeting
Business Wire - Mon Sep 21, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company will be giving a poster presentation and exhibiting at the 65th Congress of Neurological Surgeons (CNS) Annual Meeting, to be held in New Orleans, LA, September 26-30, 2015. The e-poster, titled "Novel Surgical Procedure to Implant an Investigational Neuro-Spinal Scaffold Following Myelotomy for Treatment of Acute Traumatic Spinal Cord Injury: A Safety and Feasibility Study," is co-authored by Lorianne Masuoka, M.D., Kristin Neff, M.S., Thomas Ulich, M.D., and Alex Aimetti, Ph.D. InVivo will also host a networking event at this meeting aimed at engaging and connecting with current and potential Principal Investigators in our clinical study. At this event, Dr. Nicholas Theodore from Barrow Neurological Institute, who performed the first implantation of the Neuro-Spinal Scaffold in a human patient, will be discussing his case experience and narrating his surgical video as a way to inform the neurosurgical community about our novel therapeutic approach.
NVIV: 8.81 (+0.47)
InVivo Therapeutics' CEO and Chairman, Mark Perrin, Featured on DeviceTalks by MassDevice
Business Wire - Wed Sep 16, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman of the Board, was featured on DeviceTalks, a MassDevice.com podcast, on Tuesday, September 15.
NVIV: 8.81 (+0.47)
InVivo Therapeutics Featured as an Industry Innovator by MassBio
Business Wire - Thu Sep 10, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company has been featured in MassBio HQ's new series titled "Industry Innovators," which highlights Massachusetts Biotechnology Council (MassBio) members making an impact on the life sciences industry.
NVIV: 8.81 (+0.47)
InVivo Therapeutics Announces Mount Sinai Hospital in New York City as New Site for Neuro-Spinal Scaffold(TM) Clinical Trial
Business Wire - Wed Sep 09, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that The Mount Sinai Hospital in New York has been added as a clinical site in the company's ongoing clinical study of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). The Mount Sinai Hospital is acclaimed internationally for excellence in clinical care and is one of seven hospital campuses that make up the Mount Sinai Health System.
NVIV: 8.81 (+0.47)
InVivo Therapeutics Announces Enrollment of Fifth Patient in Pilot Spinal Cord Injury Study
Business Wire - Tue Sep 08, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the fifth patient has been enrolled in the company's ongoing pilot study of its investigational Neuro-Spinal Scaffold(TM) implant in patients with acute thoracic spinal cord injury at the Keck Hospital of University of Southern California (USC) in Los Angeles.
NVIV: 8.81 (+0.47)
InVivo Therapeutics to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Business Wire - Tue Sep 01, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, is scheduled to present at the Rodman & Renshaw 17th Annual Global Investment Conference to be held September 8-10, 2015 at the St. Regis Hotel in New York City, NY. The company's presentation will be Thursday, September 10 at 1:45 PM (EDT). A live webcast will be available at http://wsw.com/webcast/rrshq25/nviv.
NVIV: 8.81 (+0.47)
InVivo Therapeutics to Present at the 17th Annual Spinal Research Network Meeting
Business Wire - Tue Aug 25, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Alex Aimetti, Ph.D., Senior Director, Medical Education and Scientific Support, will be giving a poster presentation at the 17th Annual Spinal Research Network Meeting to be held September 4-5, 2015 in London, UK. The abstract, titled "Benefits of Surgical Implantation of an Investigational Biodegradable Neuro-Spinal Scaffold in Various Animal Models of Acute Spinal Cord Contusion Injury: Clinical Translation," is co-authored by Dr. Aimetti, James Guest, M.D., Nicholas Theodore, M.D., Domagoj Coric, M.D., Lorianne Masuoka, M.D., Simon Moore, Ph.D., Richard Layer, Ph.D., and Thomas Ulich, M.D.
NVIV: 8.81 (+0.47)
InVivo Therapeutics Announces Listing Transfer to Nasdaq Global Market
Business Wire - Mon Aug 24, 8:35AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the listing of the company's common stock has been transferred to the Nasdaq Global Market. The company's common stock previously traded on the Nasdaq Capital Market and will continue to trade under the same symbol NVIV. This follows the July 29th announcement by InVivo that the company has been added to the Russell Global, Russell 3000(R), Russell 2000(R), and Russell Microcap indexes.
NVIV: 8.81 (+0.47)
InVivo Therapeutics Featured in Front Page Article in The Boston Globe
Business Wire - Mon Aug 24, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) has announced that the company and the company's ongoing trial of its investigational Neuro-Spinal Scaffold in patients with acute thoracic spinal cord injury were featured in a front page article in The Boston Globe on Sunday, August 23. The article was published on the front page of The Boston Globe's website (www.bostonglobe.com) on Friday, August 21. The story was produced by Stat, a new national publication from Boston Globe Media Partners that will launch this fall with coverage of health, medicine, and life sciences. The Boston Globe reaches over 4 million people per month between its online and print content.
NVIV: 8.81 (+0.47)
InVivo Therapeutics Announces Enrollment of Fourth Patient in Pilot Spinal Cord Injury Trial
Business Wire - Thu Aug 20, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that a fourth patient has been enrolled in the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute thoracic spinal cord injury at the UC Davis Medical Center in Sacramento, CA.
NVIV: 8.81 (+0.47)
InVivo Therapeutics' CEO and Chairman, Mark Perrin, Interviewed by Maria Bartiromo on FOX Business Network's "Mornings with Maria"
Business Wire - Thu Aug 13, 10:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman of the Board, appeared on the Fox Business Network program "Mornings with Maria" on Thursday, August 13. The program, anchored by FOX Business Global Markets Editor Maria Bartiromo, runs weekdays from 6-9 A.M. (ET) and reaches an estimated 5.3 million viewers. The groundbreaking financial journalist covers the day's top business news and interviews leaders of some of the world's largest companies.
NVIV: 8.81 (+0.47)
InVivo Therapeutics Announces New Jersey's Cooper Neurological Institute as New Clinical Site for Neuro-Spinal Scaffold
Business Wire - Wed Aug 12, 3:30PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Cooper Neurological Institute (CNI) in Camden, NJ has been added as a clinical site in the company's ongoing pilot study of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). CNI is a part of Cooper University Health Care, a network providing care to Southern New Jersey and the entire Delaware Valley. Steven Yocom, DO, Assistant Professor of Neurosurgery and Co-Director of the CNI Spine Program, has been named Principal Investigator at this site.
NVIV: 8.81 (+0.47)
InVivo Therapeutics Announces Promotions and New Organizational Roles to Further Drive Market Development and Awareness of Spinal Cord Injury Innovation
Business Wire - Thu Aug 06, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced promotions for two members of its management team.
RGEN: 25.28 (+0.76), NVIV: 8.81 (+0.47)
InVivo Therapeutics Reports 2015 Second Quarter Financial Results and Business Update
Business Wire - Wed Aug 05, 4:00PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended June 30, 2015.
NVIV: 8.81 (+0.47)